FDA's Controversial Approval of Puberty Blockers Exposed
Submitted by MAGA
Posted 99 days ago
**Shocking Revelations Surround FDA's Approval of Puberty Blockers for Kids**
Recent documents obtained by America First Legal have thrown the spotlight on the controversial practices surrounding the use of puberty blockers in minors, particularly for those identifying as transgender.
An internal email from a team leader at the U.S. Food and Drug Administration (FDA) raises grave concerns about the safety and efficacy of these drugs.
Shannon Sullivan, who oversees a clinical team at the FDA, expressed alarming findings from a safety review that revealed an "increased risk in depression and suicidality" among minors taking GnRH agonists, the class of drugs the FDA is considering for approval in transgender youth.
Despite these serious risks being acknowledged, Sullivan recommended the approval of hormonal treatments for children struggling with gender dysphoria.
Activists and proponents of experimental 'gender-affirming care' argue that these drugs are essential to prevent self-harm and suicide among children facing such identity crises.
Yet the very documents in question suggest that these treatments may instead exacerbate the very issues they claim to remedy.
Ian Prior, a senior adviser at America First Legal, condemned the FDA’s recommendation as "shocking and unacceptable." He pointed out the contradiction in promoting treatments that may cause harm under the guise of providing care.
This revelation aligns with a growing skepticism among concerned citizens, parents, and lawmakers regarding the safety of allowing minors to undergo gender transition procedures.
As Europe takes steps to reevaluate similar medical practices, many in the U.S. are calling for greater scrutiny and even a ban on experimental treatments for children.
The push for such measures reflects a broader sentiment among citizens who prioritize the health and well-being of young people over politically motivated agendas.
With this emerging narrative, the conversation around gender dysphoria treatments is rapidly evolving, demanding an honest discussion about risks, benefits, and ethical responsibility.
As Republican leaders continue to advocate for traditional family values and urge caution in pediatric care, this issue is bound to remain front and center in the national dialogue.
Parents across the nation are encouraged to become informed about these developments as the FDA prepares to handle a public policy issue with profound implications for future generations.
Sources:
miamiindependent.com
breitbart.com
dailysignal.com
Recent documents obtained by America First Legal have thrown the spotlight on the controversial practices surrounding the use of puberty blockers in minors, particularly for those identifying as transgender.
An internal email from a team leader at the U.S. Food and Drug Administration (FDA) raises grave concerns about the safety and efficacy of these drugs.
Shannon Sullivan, who oversees a clinical team at the FDA, expressed alarming findings from a safety review that revealed an "increased risk in depression and suicidality" among minors taking GnRH agonists, the class of drugs the FDA is considering for approval in transgender youth.
Despite these serious risks being acknowledged, Sullivan recommended the approval of hormonal treatments for children struggling with gender dysphoria.
Activists and proponents of experimental 'gender-affirming care' argue that these drugs are essential to prevent self-harm and suicide among children facing such identity crises.
Yet the very documents in question suggest that these treatments may instead exacerbate the very issues they claim to remedy.
Ian Prior, a senior adviser at America First Legal, condemned the FDA’s recommendation as "shocking and unacceptable." He pointed out the contradiction in promoting treatments that may cause harm under the guise of providing care.
This revelation aligns with a growing skepticism among concerned citizens, parents, and lawmakers regarding the safety of allowing minors to undergo gender transition procedures.
As Europe takes steps to reevaluate similar medical practices, many in the U.S. are calling for greater scrutiny and even a ban on experimental treatments for children.
The push for such measures reflects a broader sentiment among citizens who prioritize the health and well-being of young people over politically motivated agendas.
With this emerging narrative, the conversation around gender dysphoria treatments is rapidly evolving, demanding an honest discussion about risks, benefits, and ethical responsibility.
As Republican leaders continue to advocate for traditional family values and urge caution in pediatric care, this issue is bound to remain front and center in the national dialogue.
Parents across the nation are encouraged to become informed about these developments as the FDA prepares to handle a public policy issue with profound implications for future generations.
Sources:
miamiindependent.com
breitbart.com
dailysignal.com
Latest News